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The protective antigen (PA) subunit of anthrax toxin interacts with the integrin-like I domains of either of two cellular
receptors, ANTXR1 or ANTXR2. These I domains contain a metal ion-dependent adhesion site (MIDAS) made up of five non-
consecutive amino acid residues that coordinate a divalent metal ion that is important for PA-binding. The MIDAS residues of
integrin I domains shift depending upon whether the domain exists in a closed (ligand-unbound) or open (ligand-bound)
conformation. Of relevance to this study, the MIDAS threonine residue coordinates the metal ion only in the open I domain
conformation. Previously it was shown that the MIDAS threonine is essential for PA interaction with ANTXR1, a result
consistent with the requirement that the I domain of that receptor adopts an open conformation for PA-binding [1]. Here we
have tested the requirement for the MIDAS threonine of ANTXR2 for PA-binding. We show that the toxin can bind to a mutant
receptor lacking the MIDAS threonine and that it can use that mutant receptor to intoxicate cultured cells. These findings
suggest that an open-like configuration of the ANTXR2 MIDAS is not essential for the interaction with PA.
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INTRODUCTION
Anthrax toxin is an AB-type toxin, secreted by B. anthracis that
contributes to bacterial virulence, as well as causing many disease
symptoms. The toxin has a single B-moiety, protective antigen
(PA), for receptor binding and cytoplasmic delivery of the two
catalytic A-moieties, lethal factor (LF) and edema factor (EF) [2].
The first step of intoxication involves binding of the full-length,
83 kDa form of PA (PA83) to either of two cell surface receptors,
ANTXR1 (anthrax toxin receptor/tumor endothelial marker 8;
ATR/TEM8) or ANTXR2 (capillary morphogenesis gene 2;
CMG2) [3,4]. These receptors share a von Willebrand factor A
(VWA) or integrin inserted (I) domain, containing a metal ion
dependent adhesion site (MIDAS), which binds PA. The MIDAS is
made up of five non-consecutive, metal ion-coordinating, residues,
i.e. D50, S52, S54, T118, and D148 in the case of ANTXR2.
Ligand binding to a-integrin I domains is regulated by
a structural change from a ‘‘closed’’ or ligand-unbound confor-
mation to an ‘‘open’’ or ligand-bound conformation [5]. These
two conformations are associated with changes in divalent metal
cation coordinating residues. In the closed conformation, ion
coordination is mediated by both MIDAS serines, by the second
MIDAS aspartate, and by three water molecules. In the open
conformation, the ion is instead coordinated by a carboxylate-
containing ligand side-chain, both MIDAS serines, the MIDAS
threonine, and two water molecules. By coordinating the metal ion
only in the open conformation, the MIDAS threonine residue is
thought to increase the electrophilicity of the metal and therefore
affinity for ligand, making it critical for the structural transition
between the closed and open states of the I domain [6]. The other
major structural change that accompanies this transition is a 10A ˚
translocation of the I domain C-terminal a-helix [5].
The crystal structure of the ANTXR2-PA complex has revealed
that PA–receptor binding appears to resemble ligand binding to
the open conformation of a-integrin I domains. Namely, the
ANTXR2-bound divalent cation is directly coordinated by
a carboxylate-containing side chain (residue D683) of PA as well
as by the MIDAS threonine and serine residues, and water
molecules coordinated by the MIDAS aspartate residues (Fig. 1)
[7,8]. However, the ANTXR2-PA binding surface which includes
residues from the receptor’s I domain MIDAS face and residues
from PA domains 2 and 4 (,2000A ˚ 2) is much larger than that of
a-integrin-ligand interactions (,1300 A ˚ 2) [7,8].
Previously it was shown that, similar to a-integrin-ligand
interactions, the first MIDAS aspartate (D50) and the MIDAS
threonine (T118) are critically important for PA binding and
intoxication via ANTXR1 [1]. Mutation of the first MIDAS
aspartate abolishes metal ion binding whereas mutation of the
MIDAS threonine, while permitting metal ion binding, prevents
the MIDAS from adopting the configuration associated with the
open I domain conformation [6]. Given the importance of residue
T118 of ANTXR1 it was proposed that an open-like configuration
of the I domain of that receptor is essential for PA-binding [1].
In this report, we have tested whether the same holds true for
ANTXR2 and we show that, unlike in the case of ANTXR1,
residue T118 is not essential for the ANTXR2-PA interaction,
indicating that the I domain of ANTXR2 does not need to adopt
a classical open-like conformation to bind PA.
MATERIALS AND METHODS
DNA constructs and cell lines
Quikchange mutagenesis (Stratagene) performed on the previously
described ANTXR2-enhanced green fluorescent protein (EGFP)
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489-EGFP) and soluble ANTXR2-mycHis
fusion constructs (sCMG2) [4,9] to generate D50A and T118A
mutations with the oligonucleotide primers 59 CTT CGT CCT
GGC AAA GTC TGG GAG TG 39 and 59 CCA GTA GGA
GAG GCA TAT ATC CAT G 39, respectively. The open reading
frames of all constructs were confirmed by DNA sequencing.
PA receptor-deficient CHO-R1.1 cells, and CHO-R1.1 cells
that were engineered to stably express CMG2
489-EGFP have been
described previously [4]. CHO-R1.1 cells transduced with
retroviral vectors encoding the D50A or T118A mutant ANTXR2
proteins were either selected in medium containing G418
(Invitrogen) and/or enriched by flow cytometric sorting on the
basis of EGFP expression [4].
PA and sANTXR2 protein production
The WT and mutant sANTXR2-mycHis proteins were purified
from the extracellular supernatants of transfected human 293Free-
style cells (Invitrogen) as described elsewhere [9]. PA was prepared
from the periplasm of E. coli BL21 cells that had been transformed
withthe PA-Pet22b as described previously [9].The PA protein was
purified by FPLC with HiTrap QFF and Superose 12 (Amersham)
or HiLoad Superdex 200 (Amersham) columns, and the relative
protein puritywas determinedbyImageQuant analysis(Amersham)
of coomassie-stained protein samples following SDS-PAGE.
Cell surface receptor expression analysis
Cell surface expression of the mutant D50A and T118A ANTXR2
receptors was confirmed using a membrane-impermeable bioti-
nylating reagent (EZ-Link SuLFo-NHS-Biotin; Pierce) and pellet-
ing biotinylated proteins with immobilized streptavidin gel
(Immunopure; Pierce) essentially as described elsewhere [1]. The
pelleted samples were boiled in reducing SDS sample buffer and
subjected to SDS-PAGE using a 10% polyacrylamide gel. The
samples were then transferred to a PVDF membrane and
immunoblotted with a 1:5000 dilution of anti-GFP antibody
(118P; Covance), followed by a 1:2500 dilution of anti-mouse
HRP (Dako), in TBST (100 mM Tris pH 7.5, 150 mM NaCl,
0.1% Tween-20) with 3% non-fat milk. For control purposes,
CHO-R1.1 cells transduced with a retroviral vector encoding
cytoplasmic EGFP from pLEGFP.C1 (Clontech) were also used to
confirm that the biotinyation method used did not label
cytoplasmic proteins (data not shown).
PA binding and in vitro intoxication assays
PA binding to cells was monitored by flow cytometric analysis
following incubations of cells for 2 hours with 100 nM PA, then
with a 1:2000 dilution of an anti-PA rabbit polyclonal serum, and
a 1:500 dilution of an APC-conjugated anti-rabbit antibody
(Molecular Probes) [4]. Intoxication was monitored by incubating
samples of cells with LFN-DTA [10] and PA. These experiments
were performed either with, or without sANTXR2 inhibitor
proteins. Cell viability was measured 25–30 hours later using the
WST-1 reagent (Roche), or 45–50 hours later using the CellTiter-
glo reagent (Promega) [4,9]. The IC50 was determined as the
concentration of inhibitor at the midpoint of the soluble receptor
titration curve. In all intoxications, % cell viability is the average
from three samples, plus or minus the S.D.
RESULTS AND DISCUSSION
The T118A mutant receptor binds PA
To test the importance of ANTXR2 residue T118, it was replaced
with an alanine in the context of a human ANTXR2-EGFP fusion
Figure 1. ANTXR2 MIDAS metal ion bound by PA D683. Close-up view
of the PA-ANTXR2 generated with Molscript (PDB # ITZN) [7]. The PA
backbone is colored light blue with the D683 residue shown in cyan.
The chelate Mg
2+ ion is colored purple, the ANTXR2 Thr118 and Asp50
residues (mutated in this report) are shown in green with the other
MIDAS residues represented in orange. Water molecules and oxygen
atoms are represented by large and small red balls, respectively.
doi:10.1371/journal.pone.0000099.g001
Figure 2. The cell surface T118A mutant ANTXR2 receptor binds PA. (A) Flow cytometric analysis of PA binding to CHO-R1.1 cells and CHO-R1.1
cells engineered to express WT or mutant ANTXR2-EGFP fusion proteins. The cells were incubated with PA and then with a PA-specific antibody
followed by an APC-labeled secondary antibody.
doi:10.1371/journal.pone.0000099.g002
PA/Mutant ANTXR2 Interactions
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also changed to an alanine (a mutation that leads to loss of metal
ion binding) in ANTXR2-EGFP. The mutant ANTXR2
D50A-
EGFP and ANTXR2
T118A-EGFP proteins were then expressed in
the PA receptor-deficient cell line, CHO-R1.1 [3]. Flow
cytometric analysis performed with PA, an anti-PA antibody and
a fluoresceinated secondary antibody revealed that the T118A
mutant receptor was expressed at the cell surface and could bind
Figure 3. Soluble ANTXR2
T118A inhibits intoxication of cells. WT and mutant sANTXR2 proteins were added in increasing amounts to measure their
relative abilities to block CHO-K1 cell intoxication with PA (10
28 M) and LFN-DTA (10
210 M). Cell viability was subsequently measured using the WST-1
assay and is represented as the percentage of that seen with cells incubated with LFN-DTA alone (100% viable).
doi:10.1371/journal.pone.0000099.g003
Figure 4. The cell surface T118A mutant ANTXR2 supports intoxication. Triplicate samples of the cells shown in Fig. 2 were incubated with 10
210 M
LFN-DTA and varying concentrations of PA and cell viability was measured as described in the Fig. 3 legend.
doi:10.1371/journal.pone.0000099.g004
PA/Mutant ANTXR2 Interactions
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PA (Fig. 2). Cell surface expression of the D50A and T118A
mutant receptors was confirmed using a membrane-impermeable
biotinylating agent as described elsewhere [1] (data not shown).
As an independent measure of how the D50A and T118A
mutations affect PA binding, these mutations were introduced
independently into the soluble human ANTXR2 receptor-decoy
protein (sANTXR2) which, through binding extracellular PA, can
protect cells and animals against intoxication [4,11]. The altered
forms of sANTXR2 were tested for their abilities to protect CHO-
K1 cells from intoxication by PA and LFN-DTA. Consistent with
activity of the full-length T118A mutant and wild-type receptors,
the sANTXR2
T118A inhibitor was ,13-fold less efficient at
blocking intoxication (IC50=80 nM) as compared to WT
sANTXR2 (IC50=6 nM) (Fig. 3). As expected sANTXR2
D50A
was not a functional receptor-decoy (Fig. 3). These results confirm
that the T118A mutation receptor is still capable of PA binding.
The T118A mutant receptor supports intoxication
The T118A and D50A mutant receptors were also tested for
ability to support intoxication, when expressed in CHO-R1.1 cells,
with PA and LFN-DTA, a fusion protein with the N-terminal
portion of LF fused to the catalytic A chain of diphtheria toxin
[10]. For control purposes, these experiments were also performed
with the parental CHO-R1.1 cells, and CHO-R1.1 cells expres-
sing a wild-type form (WT) of human ANTXR2-EGFP. These
studies revealed that ANTXR2
T118A -EGFP supported intoxica-
tion albeit less efficiently than the wild-type version of the
ANTXR2 protein (Fig. 4A). By contrast, ANTXR2
D50A-EGFP
could not support intoxication (Fig. 4B), an expected result given
that this mutation completely disrupts PA binding (Fig. 2).
This report has investigated the roles played by specific metal
ion binding residues in the PA-ANTXR2 interaction. As in the
case of ANTXR1 [1], the ANTXR2 interaction with wild-type PA
is absolutely dependent upon the first receptor MIDAS aspartate
(D50). However, unlike ANTXR1, the MIDAS threonine residue
(T118) was not essential for PA interaction as judged by PA-
binding either to the mutant cell surface receptor (or to the mutant
soluble receptor). Moreover the mutant ANTXR2 protein lacking
residue T118 was capable of supporting intoxication mediated by
wild-type PA.
Taken together, these results demonstrate that there is no
absolute requirement for ANTXR2 to adopt an open-like
configuration for binding PA. Consistently, unlike ANTXR1
[1,12] ANTXR2 can bind to, and support intoxication by, mutant
PA proteins in which metal-coordinating residue D683 is replaced
by either an asparagine or a lysine [13].
The difference in the absolute requirement for an open-like
configuration of the receptor MIDAS between ANTXR1 and
ANTXR2 is presumably due, at least in part, to the fact that PA
binds the ANTXR2 I domain with an approximately 1000-fold
tighter binding affinity than it does the ANTXR1 I domain
[11,14]. We propose that it is this higher binding affinity
associated with ANTXR2 which overcomes an absolute re-
quirement for an open-like configuration of the receptor I domain.
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